Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 688 of 6351
-
New HIV prevention shot could last 4 months
Prevention OngoingThis study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
Phase 2 • Sponsor: ViiV Healthcare • Aim: Prevention
Last updated Jun 27, 2026 07:58 UTC
-
New cocktail aims to shrink untreatable liver tumors
Disease control OngoingThe main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Phase 2 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Promising new attack on tough breast cancer brain metastases
Disease control Recruiting nowThis is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Phase 1/2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New heart failure drug aims to cut hospitalizations and deaths
Disease control Recruiting nowThe purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Phase 3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Engineered immune cells aim to keep HIV in check without daily pills
Disease control Recruiting nowHuman immunodeficiency virus type 1 (HIV-1) causes a persistent infection that ultimately leads to acquired immunodeficiency syndrome (AIDS). Treatment of HIV-1 infection with combination anti-retroviral therapy (ART) suppresses HIV-1 replication to undetectable viral levels and …
Early phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could six months of immunotherapy be enough for melanoma? major trial launches
Disease control Recruiting now1. Rational Every year, around 5,000 people in Sweden are diagnosed with malignant skin melanoma. In the early stages of malignant skin melanoma, the chance of cure with surgery is very good. At a later stage, when the melanoma has become thick and/or has spread, the risk of recu…
Phase 3 • Sponsor: Uppsala University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New program aims to curb HIV and opioid crises with peer support and rapid access
Prevention Recruiting nowThe US opioid overdose epidemic has been accompanied by an increase in human immunodeficiency (HIV) among persons who inject drugs. HIV pre-exposure prophylaxis (PrEP) is an FDA approved medication taken daily orally by individuals who are HIV negative, but who are at increased r…
Sponsor: Boston Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:04 UTC
-
Electric field therapy before brain tumor surgery shows promise in early trial
Disease control Recruiting nowPreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis of glioblastoma (GBM). Participants will be required…
Sponsor: The Christie NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Can a new injection tackle obesity, diabetes, and liver disease?
Disease control CompletedThis study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, and immunogenicity of MWN105 injection in healthy…
Phase 1 • Sponsor: Shanghai Minwei Biotechnology Co., Ltd • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Could brain cell implants ease Parkinson's? new trial begins
Disease control Recruiting nowThe Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts. This study will be held in approximately 5-8 study sites in United States
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Triple-Drug attack on liver cancer shows promise in early trial
Disease control Recruiting nowThis study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).
Phase 2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to replace IVIg for nerve disease
Disease control OngoingThe main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More info…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug shows promise for Tough-to-Treat multiple myeloma
Disease control Recruiting nowThis study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
AI may forecast stroke outcomes and guide recovery
Knowledge-focused OngoingStroke is a leading cause of death and disability worldwide. The clinical validation of explainable and interpretable Artificial Intelligence (AI) solutions to assist a timely, personalised management of the acute phase of stroke, would have a major impact since it can greatly re…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Wireless sensor could help doctors Fine-Tune heart failure treatment in real time
Disease control Recruiting nowThe CardioClip study is exploring the use of a wireless sensor to monitor pressure in the pulmonary artery. This sensor is inserted much like the mTEER procedure, a non-surgical method through a vein in the groin. The investigators want to find out if the sensor, by constantly se…
Sponsor: Columbia University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New daily pill shows promise for weight loss in phase 2 trial
Disease control CompletedThis is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg…
Phase 2 • Sponsor: Viking Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New 21-Strain pneumonia vaccine shows promise in infant trial
Vaccine OngoingThis study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20-valent…
Phase 3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New pill could ease diabetic nerve pain for good
Symptom relief OngoingThe purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Engineered t cells take on Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase Ib trial tests the safety, side effects and best dose of anti-HLA-A2/NY-ESO-1 T-cell receptor (TCR)-transduced autologous T lymphocytes (A2-ESO-1 TCR-T cells) in treating patients with NY-ESO-1 overexpression positive triple negative breast cancer (TNBC) that has come …
Phase 1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental pill takes on Hard-to-Treat ovarian cancer
Disease control Recruiting nowAn open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Phase 1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC